

Clinical Oversight Review Board (CORB) Criteria for Prescribing Ublituximab (Briumvi)

Non-Formulary **ublituximab (Briumvi)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria, criteria for *current Kaiser Permanente members* already taking the medication who have not been reviewed previously, and criteria for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously:

- Prescribed by a Neurologist
- Patient has a diagnosis of Multiple Sclerosis
- Patient has tried and had an allergic reaction to infused rituximab or a rituximab biosimilar product

kp.org

Revised: 09/12/24
Effective: 11/21/24

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest